Rznomics
알지노믹스는 RNA Platform 기술 기반 항암/난치성 질환 바이오 신약 개발을 통해 다양한 unmet medical needs를 충족 가능한 핵심 역량을 보유하고 있습니다. Rewriting the Future of RNA Therapy ─ Pioneering the Next Modality with Catalytic RNA Rewriting Rewriting the Future of RNA Therapy ─ Pioneering the Next Modality with Catalytic RNA Rewriting 혁신적 RNA 기반 바이오 신약 개발을 통한 인체질환정복 구현을 위해 간암/범용 각종 암/퇴행성 질환/유전 질환에 대한 유전자 치료제 개발을 목표로 하고 있습니다.
Basic Information
- Category: Emerging Biotech
- Founded: 2018
- Headquarters: Seoul, South Korea
- Website: rznomics.com
Documented Facts
- Phone: 031-706-8730 (No linked source recorded for this statement.)
- Email: rznomics@rznomics.com (No linked source recorded for this statement.)
Evidence and Sources
- Rznomics — Official Site (official)
- Rznomics on linkedin (social)
Citation Guidance
Explore Emerging Biotech profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Rznomics.
- Canonical profile: https://brandsource.ai/brands/rznomics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/rznomics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/rznomics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (84/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T04:26:13.354Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
알지노믹스는 RNA Platform 기술 기반 항암/난치성 질환 바이오 신약 개발을 통해 다양한 unmet medical needs를 충족 가능한 핵심 역량을 보유하고 있습니다. Rewriting the Future of RNA Therapy ─ Pioneering the Next Modality with Catalytic RNA Rewriting Rewriting the Future of RNA Therapy ─ Pioneering the Next Modality with Catalytic RNA Rewriting 혁신적 RNA 기반 바이오 신약 개발을 통한 인체질환정복 구현을 위해 간암/범용 각종 암/퇴행성 질환/유전 질환에 대한 유전자 치료제 개발을 목표로 하고 있습니다.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.